

Global Cancer Drug based on PARP Inhibitor Market Growth 2023-2029

<https://marketpublishers.com/r/GAC8FBC3517DEN.html>

Date: March 2023

Pages: 92

Price: US\$ 3,660.00 (Single User License)

ID: GAC8FBC3517DEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP)

LPI (LP Information)' newest research report, the "Cancer Drug based on PARP Inhibitor Industry Forecast" looks at past sales and reviews total world Cancer Drug based on PARP Inhibitor sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Drug based on PARP Inhibitor sales for 2023 through 2029. With Cancer Drug based on PARP Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Cancer Drug based on PARP Inhibitor industry.

This Insight Report provides a comprehensive analysis of the global Cancer Drug based on PARP Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Drug based on PARP Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cancer Drug based on PARP Inhibitor market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Drug based on PARP Inhibitor and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced

view of the current state and future trajectory in the global Cancer Drug based on PARP Inhibitor.

The global Cancer Drug based on PARP Inhibitor market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Cancer Drug based on PARP Inhibitor is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Cancer Drug based on PARP Inhibitor is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Cancer Drug based on PARP Inhibitor is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Cancer Drug based on PARP Inhibitor players cover AstraZeneca, Merck & Co, GSK, Clovis Oncology, Pfizer and Zai Lab, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Drug based on PARP Inhibitor market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Lynparza

ZeJula

Rubraca

Talzenna

Segmentation by application

Ovarian Cancer

Breast Cancer

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

AstraZeneca

Merck & Co

GSK

Clovis Oncology

Pfizer

Zai Lab

Key Questions Addressed in this Report

What is the 10-year outlook for the global Cancer Drug based on PARP Inhibitor

Global Cancer Drug based on PARP Inhibitor Market Growth 2023-2029

market?

What factors are driving Cancer Drug based on PARP Inhibitor market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Cancer Drug based on PARP Inhibitor market opportunities vary by end market size?

How does Cancer Drug based on PARP Inhibitor break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Cancer Drug based on PARP Inhibitor Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Cancer Drug based on PARP Inhibitor by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Cancer Drug based on PARP Inhibitor by Country/Region, 2018, 2022 & 2029
- 2.2 Cancer Drug based on PARP Inhibitor Segment by Type
 - 2.2.1 Lynparza
 - 2.2.2 Zejula
 - 2.2.3 Rubraca
 - 2.2.4 Talzenna
- 2.3 Cancer Drug based on PARP Inhibitor Sales by Type
 - 2.3.1 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Cancer Drug based on PARP Inhibitor Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Cancer Drug based on PARP Inhibitor Sale Price by Type (2018-2023)
- 2.4 Cancer Drug based on PARP Inhibitor Segment by Application
 - 2.4.1 Ovarian Cancer
 - 2.4.2 Breast Cancer
 - 2.4.3 Other
- 2.5 Cancer Drug based on PARP Inhibitor Sales by Application
 - 2.5.1 Global Cancer Drug based on PARP Inhibitor Sale Market Share by Application (2018-2023)

2.5.2 Global Cancer Drug based on PARP Inhibitor Revenue and Market Share by Application (2018-2023)

2.5.3 Global Cancer Drug based on PARP Inhibitor Sale Price by Application (2018-2023)

3 GLOBAL CANCER DRUG BASED ON PARP INHIBITOR BY COMPANY

3.1 Global Cancer Drug based on PARP Inhibitor Breakdown Data by Company

3.1.1 Global Cancer Drug based on PARP Inhibitor Annual Sales by Company (2018-2023)

3.1.2 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Company (2018-2023)

3.2 Global Cancer Drug based on PARP Inhibitor Annual Revenue by Company (2018-2023)

3.2.1 Global Cancer Drug based on PARP Inhibitor Revenue by Company (2018-2023)

3.2.2 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Company (2018-2023)

3.3 Global Cancer Drug based on PARP Inhibitor Sale Price by Company

3.4 Key Manufacturers Cancer Drug based on PARP Inhibitor Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Cancer Drug based on PARP Inhibitor Product Location Distribution

3.4.2 Players Cancer Drug based on PARP Inhibitor Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR CANCER DRUG BASED ON PARP INHIBITOR BY GEOGRAPHIC REGION

4.1 World Historic Cancer Drug based on PARP Inhibitor Market Size by Geographic Region (2018-2023)

4.1.1 Global Cancer Drug based on PARP Inhibitor Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Cancer Drug based on PARP Inhibitor Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Cancer Drug based on PARP Inhibitor Market Size by Country/Region (2018-2023)

4.2.1 Global Cancer Drug based on PARP Inhibitor Annual Sales by Country/Region (2018-2023)

4.2.2 Global Cancer Drug based on PARP Inhibitor Annual Revenue by Country/Region (2018-2023)

4.3 Americas Cancer Drug based on PARP Inhibitor Sales Growth

4.4 APAC Cancer Drug based on PARP Inhibitor Sales Growth

4.5 Europe Cancer Drug based on PARP Inhibitor Sales Growth

4.6 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Growth

5 AMERICAS

5.1 Americas Cancer Drug based on PARP Inhibitor Sales by Country

5.1.1 Americas Cancer Drug based on PARP Inhibitor Sales by Country (2018-2023)

5.1.2 Americas Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2023)

5.2 Americas Cancer Drug based on PARP Inhibitor Sales by Type

5.3 Americas Cancer Drug based on PARP Inhibitor Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Cancer Drug based on PARP Inhibitor Sales by Region

6.1.1 APAC Cancer Drug based on PARP Inhibitor Sales by Region (2018-2023)

6.1.2 APAC Cancer Drug based on PARP Inhibitor Revenue by Region (2018-2023)

6.2 APAC Cancer Drug based on PARP Inhibitor Sales by Type

6.3 APAC Cancer Drug based on PARP Inhibitor Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Cancer Drug based on PARP Inhibitor by Country

7.1.1 Europe Cancer Drug based on PARP Inhibitor Sales by Country (2018-2023)

7.1.2 Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2023)

7.2 Europe Cancer Drug based on PARP Inhibitor Sales by Type

7.3 Europe Cancer Drug based on PARP Inhibitor Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Cancer Drug based on PARP Inhibitor by Country

8.1.1 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Country (2018-2023)

8.1.2 Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2023)

8.2 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Type

8.3 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Cancer Drug based on PARP Inhibitor

10.3 Manufacturing Process Analysis of Cancer Drug based on PARP Inhibitor

10.4 Industry Chain Structure of Cancer Drug based on PARP Inhibitor

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Cancer Drug based on PARP Inhibitor Distributors

11.3 Cancer Drug based on PARP Inhibitor Customer

12 WORLD FORECAST REVIEW FOR CANCER DRUG BASED ON PARP INHIBITOR BY GEOGRAPHIC REGION

12.1 Global Cancer Drug based on PARP Inhibitor Market Size Forecast by Region

12.1.1 Global Cancer Drug based on PARP Inhibitor Forecast by Region (2024-2029)

12.1.2 Global Cancer Drug based on PARP Inhibitor Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Cancer Drug based on PARP Inhibitor Forecast by Type

12.7 Global Cancer Drug based on PARP Inhibitor Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 AstraZeneca

13.1.1 AstraZeneca Company Information

13.1.2 AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

13.1.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 AstraZeneca Main Business Overview

13.1.5 AstraZeneca Latest Developments

13.2 Merck & Co

13.2.1 Merck & Co Company Information

13.2.2 Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

13.2.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and

Gross Margin (2018-2023)

13.2.4 Merck & Co Main Business Overview

13.2.5 Merck & Co Latest Developments

13.3 GSK

13.3.1 GSK Company Information

13.3.2 GSK Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

13.3.3 GSK Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 GSK Main Business Overview

13.3.5 GSK Latest Developments

13.4 Clovis Oncology

13.4.1 Clovis Oncology Company Information

13.4.2 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

13.4.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Clovis Oncology Main Business Overview

13.4.5 Clovis Oncology Latest Developments

13.5 Pfizer

13.5.1 Pfizer Company Information

13.5.2 Pfizer Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

13.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Pfizer Main Business Overview

13.5.5 Pfizer Latest Developments

13.6 Zai Lab

13.6.1 Zai Lab Company Information

13.6.2 Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

13.6.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Zai Lab Main Business Overview

13.6.5 Zai Lab Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Cancer Drug based on PARP Inhibitor Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Cancer Drug based on PARP Inhibitor Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Lynparza

Table 4. Major Players of Zejula

Table 5. Major Players of Rubraca

Table 6. Major Players of Talzenna

Table 7. Global Cancer Drug based on PARP Inhibitor Sales by Type (2018-2023) & (K Units)

Table 8. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2023)

Table 9. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2023) & (\$ million)

Table 10. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2018-2023)

Table 11. Global Cancer Drug based on PARP Inhibitor Sale Price by Type (2018-2023) & (US\$/Unit)

Table 12. Global Cancer Drug based on PARP Inhibitor Sales by Application (2018-2023) & (K Units)

Table 13. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2023)

Table 14. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2023)

Table 15. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2018-2023)

Table 16. Global Cancer Drug based on PARP Inhibitor Sale Price by Application (2018-2023) & (US\$/Unit)

Table 17. Global Cancer Drug based on PARP Inhibitor Sales by Company (2018-2023) & (K Units)

Table 18. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Company (2018-2023)

Table 19. Global Cancer Drug based on PARP Inhibitor Revenue by Company (2018-2023) (\$ Millions)

Table 20. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by

Company (2018-2023)

Table 21. Global Cancer Drug based on PARP Inhibitor Sale Price by Company (2018-2023) & (US\$/Unit)

Table 22. Key Manufacturers Cancer Drug based on PARP Inhibitor Producing Area Distribution and Sales Area

Table 23. Players Cancer Drug based on PARP Inhibitor Products Offered

Table 24. Cancer Drug based on PARP Inhibitor Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Cancer Drug based on PARP Inhibitor Sales by Geographic Region (2018-2023) & (K Units)

Table 28. Global Cancer Drug based on PARP Inhibitor Sales Market Share Geographic Region (2018-2023)

Table 29. Global Cancer Drug based on PARP Inhibitor Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 30. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Geographic Region (2018-2023)

Table 31. Global Cancer Drug based on PARP Inhibitor Sales by Country/Region (2018-2023) & (K Units)

Table 32. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Country/Region (2018-2023)

Table 33. Global Cancer Drug based on PARP Inhibitor Revenue by Country/Region (2018-2023) & (\$ millions)

Table 34. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Country/Region (2018-2023)

Table 35. Americas Cancer Drug based on PARP Inhibitor Sales by Country (2018-2023) & (K Units)

Table 36. Americas Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2018-2023)

Table 37. Americas Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2023) & (\$ Millions)

Table 38. Americas Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2018-2023)

Table 39. Americas Cancer Drug based on PARP Inhibitor Sales by Type (2018-2023) & (K Units)

Table 40. Americas Cancer Drug based on PARP Inhibitor Sales by Application (2018-2023) & (K Units)

Table 41. APAC Cancer Drug based on PARP Inhibitor Sales by Region (2018-2023) &

(K Units)

Table 42. APAC Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2018-2023)

Table 43. APAC Cancer Drug based on PARP Inhibitor Revenue by Region (2018-2023) & (\$ Millions)

Table 44. APAC Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2018-2023)

Table 45. APAC Cancer Drug based on PARP Inhibitor Sales by Type (2018-2023) & (K Units)

Table 46. APAC Cancer Drug based on PARP Inhibitor Sales by Application (2018-2023) & (K Units)

Table 47. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2018-2023) & (K Units)

Table 48. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2018-2023)

Table 49. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2023) & (\$ Millions)

Table 50. Europe Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2018-2023)

Table 51. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2018-2023) & (K Units)

Table 52. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2018-2023) & (K Units)

Table 53. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Country (2018-2023) & (K Units)

Table 54. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2018-2023)

Table 55. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2023) & (\$ Millions)

Table 56. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue Market Share by Country (2018-2023)

Table 57. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Type (2018-2023) & (K Units)

Table 58. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales by Application (2018-2023) & (K Units)

Table 59. Key Market Drivers & Growth Opportunities of Cancer Drug based on PARP Inhibitor

Table 60. Key Market Challenges & Risks of Cancer Drug based on PARP Inhibitor

Table 61. Key Industry Trends of Cancer Drug based on PARP Inhibitor

Table 62. Cancer Drug based on PARP Inhibitor Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Cancer Drug based on PARP Inhibitor Distributors List
Table 65. Cancer Drug based on PARP Inhibitor Customer List
Table 66. Global Cancer Drug based on PARP Inhibitor Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Cancer Drug based on PARP Inhibitor Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 68. Americas Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Cancer Drug based on PARP Inhibitor Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 70. APAC Cancer Drug based on PARP Inhibitor Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Cancer Drug based on PARP Inhibitor Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 72. Europe Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Cancer Drug based on PARP Inhibitor Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 74. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 76. Global Cancer Drug based on PARP Inhibitor Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Cancer Drug based on PARP Inhibitor Revenue Forecast by Type (2024-2029) & (\$ Millions)
Table 78. Global Cancer Drug based on PARP Inhibitor Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Cancer Drug based on PARP Inhibitor Revenue Forecast by Application (2024-2029) & (\$ Millions)
Table 80. AstraZeneca Basic Information, Cancer Drug based on PARP Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 81. AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications
Table 82. AstraZeneca Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
Table 83. AstraZeneca Main Business

Table 84. AstraZeneca Latest Developments

Table 85. Merck & Co Basic Information, Cancer Drug based on PARP Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 86. Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

Table 87. Merck & Co Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 88. Merck & Co Main Business

Table 89. Merck & Co Latest Developments

Table 90. GSK Basic Information, Cancer Drug based on PARP Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 91. GSK Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

Table 92. GSK Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 93. GSK Main Business

Table 94. GSK Latest Developments

Table 95. Clovis Oncology Basic Information, Cancer Drug based on PARP Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 96. Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

Table 97. Clovis Oncology Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 98. Clovis Oncology Main Business

Table 99. Clovis Oncology Latest Developments

Table 100. Pfizer Basic Information, Cancer Drug based on PARP Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 101. Pfizer Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

Table 102. Pfizer Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 103. Pfizer Main Business

Table 104. Pfizer Latest Developments

Table 105. Zai Lab Basic Information, Cancer Drug based on PARP Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 106. Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolios and Specifications

Table 107. Zai Lab Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 108. Zai Lab Main Business

Table 109. Zai Lab Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Cancer Drug based on PARP Inhibitor
- Figure 2. Cancer Drug based on PARP Inhibitor Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Cancer Drug based on PARP Inhibitor Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Cancer Drug based on PARP Inhibitor Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Cancer Drug based on PARP Inhibitor Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Lynparza
- Figure 10. Product Picture of Zejula
- Figure 11. Product Picture of Rubraca
- Figure 12. Product Picture of Talzenna
- Figure 13. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type in 2022
- Figure 14. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2018-2023)
- Figure 15. Cancer Drug based on PARP Inhibitor Consumed in Ovarian Cancer
- Figure 16. Global Cancer Drug based on PARP Inhibitor Market: Ovarian Cancer (2018-2023) & (K Units)
- Figure 17. Cancer Drug based on PARP Inhibitor Consumed in Breast Cancer
- Figure 18. Global Cancer Drug based on PARP Inhibitor Market: Breast Cancer (2018-2023) & (K Units)
- Figure 19. Cancer Drug based on PARP Inhibitor Consumed in Other
- Figure 20. Global Cancer Drug based on PARP Inhibitor Market: Other (2018-2023) & (K Units)
- Figure 21. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2022)
- Figure 22. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application in 2022
- Figure 23. Cancer Drug based on PARP Inhibitor Sales Market by Company in 2022 (K Units)
- Figure 24. Global Cancer Drug based on PARP Inhibitor Sales Market Share by

Company in 2022

Figure 25. Cancer Drug based on PARP Inhibitor Revenue Market by Company in 2022 (\$ Million)

Figure 26. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Company in 2022

Figure 27. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Geographic Region (2018-2023)

Figure 28. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Geographic Region in 2022

Figure 29. Americas Cancer Drug based on PARP Inhibitor Sales 2018-2023 (K Units)

Figure 30. Americas Cancer Drug based on PARP Inhibitor Revenue 2018-2023 (\$ Millions)

Figure 31. APAC Cancer Drug based on PARP Inhibitor Sales 2018-2023 (K Units)

Figure 32. APAC Cancer Drug based on PARP Inhibitor Revenue 2018-2023 (\$ Millions)

Figure 33. Europe Cancer Drug based on PARP Inhibitor Sales 2018-2023 (K Units)

Figure 34. Europe Cancer Drug based on PARP Inhibitor Revenue 2018-2023 (\$ Millions)

Figure 35. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales 2018-2023 (K Units)

Figure 36. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue 2018-2023 (\$ Millions)

Figure 37. Americas Cancer Drug based on PARP Inhibitor Sales Market Share by Country in 2022

Figure 38. Americas Cancer Drug based on PARP Inhibitor Revenue Market Share by Country in 2022

Figure 39. Americas Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2023)

Figure 40. Americas Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2023)

Figure 41. United States Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Canada Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 43. Mexico Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 44. Brazil Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 45. APAC Cancer Drug based on PARP Inhibitor Sales Market Share by Region

in 2022

Figure 46. APAC Cancer Drug based on PARP Inhibitor Revenue Market Share by Regions in 2022

Figure 47. APAC Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2023)

Figure 48. APAC Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2023)

Figure 49. China Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 50. Japan Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 51. South Korea Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Southeast Asia Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 53. India Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 54. Australia Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 55. China Taiwan Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 56. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Country in 2022

Figure 57. Europe Cancer Drug based on PARP Inhibitor Revenue Market Share by Country in 2022

Figure 58. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2023)

Figure 59. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2023)

Figure 60. Germany Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 61. France Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 62. UK Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Italy Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 64. Russia Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 65. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Country in 2022

Figure 66. Middle East & Africa Cancer Drug based on PARP Inhibitor Revenue Market Share by Country in 2022

Figure 67. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2023)

Figure 68. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2023)

Figure 69. Egypt Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 70. South Africa Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Israel Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Turkey Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 73. GCC Country Cancer Drug based on PARP Inhibitor Revenue Growth 2018-2023 (\$ Millions)

Figure 74. Manufacturing Cost Structure Analysis of Cancer Drug based on PARP Inhibitor in 2022

Figure 75. Manufacturing Process Analysis of Cancer Drug based on PARP Inhibitor

Figure 76. Industry Chain Structure of Cancer Drug based on PARP Inhibitor

Figure 77. Channels of Distribution

Figure 78. Global Cancer Drug based on PARP Inhibitor Sales Market Forecast by Region (2024-2029)

Figure 79. Global Cancer Drug based on PARP Inhibitor Revenue Market Share Forecast by Region (2024-2029)

Figure 80. Global Cancer Drug based on PARP Inhibitor Sales Market Share Forecast by Type (2024-2029)

Figure 81. Global Cancer Drug based on PARP Inhibitor Revenue Market Share Forecast by Type (2024-2029)

Figure 82. Global Cancer Drug based on PARP Inhibitor Sales Market Share Forecast by Application (2024-2029)

Figure 83. Global Cancer Drug based on PARP Inhibitor Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Cancer Drug based on PARP Inhibitor Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GAC8FBC3517DEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAC8FBC3517DEN.html>